Skip to Main Content

Paper Details

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Blood
15
2023
CC-486, CD30, CD30-negative PTCL, DNMT3A, IDH2, IDH2 mutations, PTCL, PTCL-, PTCL-TFH, Peripheral T-cell lymphomas, RHOA, T-follicular helper phenotype, TET2, TET2 mutations, azacitidine, cyclophosphamide, doxorubicin, fatigue, febrile neutropenia, gastrointestinal symptoms, genes, hematologic toxicities, neutropenia, patients, prednisone, tumor, tumor samples, vincristine
Author NameAffiliation
Zhengming ChenMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Andrea SbonerMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Andrea SbonerMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Michael SigourosMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Koen van BesienMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Jenny XiangMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Ari MelnickMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Olivier ElementoMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Olivier ElementoMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Giorgio InghiramiMeyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
  • 1 - 10

Datasets

Release 1.2